Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Muniz

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Materials (Basel, Switzerland)|October 19, 2019
Fatigue Assessment Strategy Using Bayesian TechniquesEnrique Castillo, Miguel Muniz-Calvente, Alfonso Fernández-Canteli, et al.
Clinical Nuclear Medicine|February 20, 2024
Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation TherapyMiguel Muniz, Daniel S Childs, Jacob J Orme, et al.
Haematologica|April 3, 2025
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapyYael Kusne, Osama M Mosalem, Jaxon Quillen, et al.
EJNMMI Research|March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targetingEmirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Clinical Genitourinary Cancer|June 22, 2026
Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA ProfilingNancy Wei, Jamie J O'Byrne, Miguel Muniz, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Neurologic Symptoms After <sup>177</sup>Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center ExperienceGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2014
A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantationErin Qualter, Prakash Satwani, Angela Ricci, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Materials (Basel, Switzerland)|October 19, 2019
Fatigue Assessment Strategy Using Bayesian TechniquesEnrique Castillo, Miguel Muniz-Calvente, Alfonso Fernández-Canteli, et al.
Clinical Nuclear Medicine|February 20, 2024
Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation TherapyMiguel Muniz, Daniel S Childs, Jacob J Orme, et al.
Haematologica|April 3, 2025
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapyYael Kusne, Osama M Mosalem, Jaxon Quillen, et al.
EJNMMI Research|March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targetingEmirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Clinical Genitourinary Cancer|June 22, 2026
Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA ProfilingNancy Wei, Jamie J O'Byrne, Miguel Muniz, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Neurologic Symptoms After <sup>177</sup>Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center ExperienceGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2014
A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantationErin Qualter, Prakash Satwani, Angela Ricci, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
Pageof 2